Climate Change Data

Genovate Biotechnology CO., LTD.

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Replaced heavy oil with natural gas for boiler fuel, reducing environmental impact.
  • Implemented waste sorting and paper recycling policies.

Social Achievements

  • Provided employees with comprehensive annual health checkups, including cancer screening.
  • Offered group insurance (including spouse/children coverage) and various welfare benefits.
  • Maintained harmonious labor-management relations through regular meetings and employee incentives.
  • Achieved “Accredited Healthy Workplace” designation from the Health Promotion Administration of MOHW.

Governance Achievements

  • Established an audit committee and a remuneration committee.
  • Implemented a comprehensive internal control system.
  • Consistently aligned planning and business strategies with corporate governance principles.
  • Completed board of directors' performance evaluation with a high overall score.

Climate Goals & Targets

Long-term Goals:
  • Continuously generate profits, maintain sustainable operations, and fulfill corporate social responsibilities.
Medium-term Goals:
  • Implement the innovative R&D mode of industry-academia collaboration and industry alliances.
  • Enhance the company's value through strategic alliances.
Short-term Goals:
  • Invest in factory software and hardware to enhance PIC/S GMP production quality and expand production capacity.
  • Reduce raw material costs and improve production processes.
  • Expand into other biomedical product fields.

Environmental Challenges

  • High risk in developing new drugs.
  • Long product development schedules.
  • Tightening of drug price reimbursements by the National Health Insurance.
  • Lack of experience in supplying and selling medicines to large hospitals.
  • Global supply chain remains turbulent due to geopolitical rivalries and conflicts.
Mitigation Strategies
  • Develop new drugs with lower risks, seeking joint development partners and government subsidies.
  • Effectively control product development schedules and collaborate with international pharmaceutical companies.
  • Actively expand into the international market and develop non-reimbursable items.
  • Cultivate relationships with main department doctors and patient associations.
  • Establish a flexible procurement system and conduct an exhaustive search for raw material suppliers.
  • Invest in new automated machinery and tools to enhance the production process.

Supply Chain Management

Supplier Audits: 203 suppliers audited in 2023

Responsible Procurement
  • Diverse procurement strategy with at least two suppliers for each main raw material.
  • Strict quality standards, inspection, and evaluation procedures for upstream and downstream manufacturers.

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events, factory damage, production line shutdowns
Transition Risks
  • Supply chain disruptions
Opportunities
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: IFRS

Certifications: PIC/S GMP

Third-party Assurance: PricewaterhouseCoopers Taiwan

Sustainable Products & Innovation

  • PMR (Anti-intermittent claudication drug)
  • GX17 immunomodulatory drugs

Awards & Recognition

  • Accredited Healthy Workplace designation from the Health Promotion Administration of MOHW